Sign In

Login

Password

Forgot Password ? Sign Up

MGS-0039 (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "MGS-0039" in Portuguese language version.

refsWebsite
Global rank Portuguese rank
10nih.gov
4th place
8th place
10doi.org
2nd place
4th place

doi.org

dx.doi.org

  • Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. (março de 2004). «MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity». Neuropharmacology. 46: 457–67. PMID 14975669. doi:10.1016/j.neuropharm.2003.10.009 
  • Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, et al. (agosto de 2004). «Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists». Journal of Medicinal Chemistry. 47: 4570–87. PMID 15317467. doi:10.1021/jm0400294 
  • Shimazaki T, Iijima M, Chaki S (outubro de 2004). «Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test». European Journal of Pharmacology. 501: 121–5. PMID 15464070. doi:10.1016/j.ejphar.2004.08.016 
  • Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, et al. (junho de 2006). «Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential». Bioorganic & Medicinal Chemistry. 14: 4193–207. PMID 16487713. doi:10.1016/j.bmc.2006.01.060 
  • Yoshimizu T, Shimazaki T, Ito A, Chaki S (julho de 2006). «An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats». Psychopharmacology. 186: 587–93. PMID 16612616. doi:10.1007/s00213-006-0390-7 
  • Stachowicz K, Wierońska J, Domin H, Chaki S, Pilc A (2011). «Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent». Pharmacological Reports. 63: 880–7. PMID 22001975. doi:10.1016/S1734-1140(11)70603-X 
  • Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A (abril de 2005). «Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors». Neuroscience Letters. 378: 131–4. PMID 15781145. doi:10.1016/j.neulet.2004.12.021 
  • Karasawa J, Yoshimizu T, Chaki S (janeiro de 2006). «A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell». Neuroscience Letters. 393: 127–30. PMID 16233956. doi:10.1016/j.neulet.2005.09.058 
  • Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A (dezembro de 2010). «On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039». Psychopharmacology. 212: 523–35. PMC 2981731Acessível livremente. PMID 20703449. doi:10.1007/s00213-010-1978-5 
  • Koike H, Iijima M, Chaki S (dezembro de 2011). «Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists». Neuropharmacology. 61: 1419–23. PMID 21903115. doi:10.1016/j.neuropharm.2011.08.034 

nih.gov

ncbi.nlm.nih.gov

  • Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. (março de 2004). «MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity». Neuropharmacology. 46: 457–67. PMID 14975669. doi:10.1016/j.neuropharm.2003.10.009 
  • Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, et al. (agosto de 2004). «Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists». Journal of Medicinal Chemistry. 47: 4570–87. PMID 15317467. doi:10.1021/jm0400294 
  • Shimazaki T, Iijima M, Chaki S (outubro de 2004). «Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test». European Journal of Pharmacology. 501: 121–5. PMID 15464070. doi:10.1016/j.ejphar.2004.08.016 
  • Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, et al. (junho de 2006). «Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential». Bioorganic & Medicinal Chemistry. 14: 4193–207. PMID 16487713. doi:10.1016/j.bmc.2006.01.060 
  • Yoshimizu T, Shimazaki T, Ito A, Chaki S (julho de 2006). «An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats». Psychopharmacology. 186: 587–93. PMID 16612616. doi:10.1007/s00213-006-0390-7 
  • Stachowicz K, Wierońska J, Domin H, Chaki S, Pilc A (2011). «Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent». Pharmacological Reports. 63: 880–7. PMID 22001975. doi:10.1016/S1734-1140(11)70603-X 
  • Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A (abril de 2005). «Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors». Neuroscience Letters. 378: 131–4. PMID 15781145. doi:10.1016/j.neulet.2004.12.021 
  • Karasawa J, Yoshimizu T, Chaki S (janeiro de 2006). «A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell». Neuroscience Letters. 393: 127–30. PMID 16233956. doi:10.1016/j.neulet.2005.09.058 
  • Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A (dezembro de 2010). «On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039». Psychopharmacology. 212: 523–35. PMC 2981731Acessível livremente. PMID 20703449. doi:10.1007/s00213-010-1978-5 
  • Koike H, Iijima M, Chaki S (dezembro de 2011). «Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists». Neuropharmacology. 61: 1419–23. PMID 21903115. doi:10.1016/j.neuropharm.2011.08.034